Ben handles patent applications spanning a broad range of chemical technologies. He specialises in particular in pharmaceutical chemistry, including new chemical entities, drug delivery formulations, nanomaterials, medical uses, dosing regimens and combination therapies.
Ben represents clients at all stages of the development process, from small-molecule target identification to clinical trial drug candidates and marketed drug products. His clients include large multinational pharmaceutical companies, universities and SMEs. He and his team are responsible for high-value European portfolios for a number of clients covering EMA and US FDA-approved drug products, advising clients on the strategic use of IP to deliver on their commercial objectives.
Alongside the drafting and prosecution of patent applications, Ben’s has an excellent track record in defending his clients’ patents in EPO opposition and appeal proceedings covering a number of commercially important drugs. Ben also has particular expertise in obtaining supplementary protection certificate protection (patent term extension) across Europe for approved drug products and regularly presents on this topic in the UK and US.
Ben also has extensive experience in diligence and opinion work, advising early-stage drug development companies in successful investment/fundraising rounds and large pharmaceutical companies with merger & acquisition diligence as well as with stage gate reviews as companies move products through to the clinic. Ben prides himself on delivering an excellent client experience and aims to bring a human side to the advice he provides.
Ben graduated with an Master’s in Chemistry (MSci) from Imperial College London. His degree included an eight-month research project on cell-penetrating peptides carried out at the École normale supérieure, in Paris. During this time he gained a good knowledge of French.